In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Advertisement
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Modus CEO On Its Plans For An At-Home Injectable For Sickle Cell Crises

Modus Therapeutics has begun a Phase I study with subcutaneously administered sevuparin. Its CEO says this new formulation of its lead asset has the potential to be self-administered by sickle cell disease patients at home for the treatment of vaso-occlusive crises.

Clinical Trials Companies

Novo Nordisk CSO: Hemophilia Treatment ‘Segmenting’ Much Like In Diabetes

Novo Nodisk's CSO says FDA approval of extended half-life Factor VIII Esperoct treatment for people with hemophilia A will give more choice to those patients and "effectively completes" the Danish group's hitherto R&D efforts based on clotting factor deficiencies. 

Approvals Blood & Coagulation Disorders

Pioneering Gyroscope Therapeutics Aims To Develop One-Time Gene Therapy For AMD

Gyroscope Therapeutics, which aims to develop genetically defined therapies for a range of eye diseases, has begun dosing in a Phase I/II clinical trial in dry age-related macular degeneration using its lead candidate.

Clinical Trials Companies

Troubled Realm Therapeutics Selling Assets, Delisting From London AIM

US-based, UK-listed biotech says it is talking with 'interested parties' including those considering making an offer for the business.

Business Strategies Commercial

Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes

Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.

Business Strategies Commercial

US Rights Deal Will Make Proleukin Clinigen's Biggest Product

Clinigen's planned purchase of US rights to Proleukin will give it global ownership of the IL-2 drug.

Business Strategies Deals
See All
Advertisement
UsernamePublicRestriction

Register